<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364399</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-MUMPS-4006</org_study_id>
    <nct_id>NCT04364399</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine</brief_title>
  <official_title>Randomized, Double-blind, Controlled Phase Ⅳ Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine in Healthy Infants Aged 8 ~12 Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac (Dalian) Vaccine Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac (Dalian) Vaccine Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of mumps vaccine in
      healthy infants aged 8-12months, compared with measles, mumps and rubella combined vaccine,
      live (MMRV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double-blind, controlled phase Ⅳ clinical trial. And 920 infants
      will be assigned to investigational group and controlled group in a 1:1 ratio. The
      investigational vaccine is manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The
      controlled vaccine is manufactured by Shanghai institute of biological products Co., Ltd.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The seroconversion rate of hemagglutination inhibition (HI) antibody</measure>
    <time_frame>the 30th day after vaccination</time_frame>
    <description>Immunogenicity index, One of the standard to evaluate the immunogenicity of experimental vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The GMT of HI antibody</measure>
    <time_frame>the 30th day after vaccination</time_frame>
    <description>Immunogenicity index, Another standard to evaluate the immunogenicity of experimental vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of the solicited local and systemic adverse reactions</measure>
    <time_frame>from day 0 to day 14 after vaccination</time_frame>
    <description>Safety index, The adverse reactions refers to the adverse events which were considered related to the vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of the unsolicited adverse events</measure>
    <time_frame>from day 0 to day 30 after immunization</time_frame>
    <description>Safety Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of the serious adverse events</measure>
    <time_frame>from day 0 to day 30 after immunization</time_frame>
    <description>Safety Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">920</enrollment>
  <condition>Mumps</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mumps vaccine, one dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>measles, mumps and rubella combined vaccine, live, one dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mumps vaccine</intervention_name>
    <description>One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>measles, mumps and rubella combined vaccine, live</intervention_name>
    <description>One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers between 8 - 12 months old;

          -  Proven legal identity;

          -  Written consent of the guardian(s) of the volunteer

        Exclusion Criteria:

          -  Received mumps vaccine or vaccine containing mumps virus;

          -  History of mumps;

          -  Axillary temperature &gt; 37.4 °C;

          -  History of allergy to any vaccine or vaccine ingredient;

          -  History of serious adverse reaction(s) to vaccination, such as urticaria, difficulty
             in breathing, angioneurotic edema, abdominal pain, etc;

          -  Autoimmune disease or immunodeficiency or immunosuppression;

          -  Congenital malformation, genetic defects, severe malnutrition;

          -  Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency,
             coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation
             disorders;

          -  Severe chronic diseases (e.g., severe cardiovascular disease, liver and kidney disease
             beyond the control of drugs, or cancer)

          -  Severe neurological disorders (epilepsy, seizures or convulsions) or psychosis;

          -  History of thyroidectomy, absence of spleen, functional absence of spleen, and any
             condition resulting from absence of spleen or splenectomy;

          -  Receipt of any of the following products:

               1. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;

               2. Any live attenuated vaccine within 28 days prior to study entry;

               3. Any other investigational medicine(s) or vaccine within 30 days prior to study
                  entry;

               4. Blood product within 3 months prior to study entry;

               5. Any immunosuppressant, cytotoxic medicine, or oral corticosteroids;

               6. Any of the acute disease or attack of the chronic disease within 7 days;

               7. Pregnant in cohabitants or congenital immune diseases;

               8. Based on the judgment of investigator(s), there was any condition indicating that
                  the subject should be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Months</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lirong Huang, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lirong Huang, Bachelor</last_name>
    <phone>86-0771-2442599</phone>
    <email>hlr620@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hezhou Center for Disease Prevention and Control</name>
      <address>
        <city>Hezhou</city>
        <state>Guangxi</state>
        <zip>542699</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianbiao Li, Bachelor</last_name>
      <phone>86-18978463935</phone>
      <email>zscdcxmb8989268@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianbiao Li, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mumps</keyword>
  <keyword>Mumps vaccine</keyword>
  <keyword>measles, mumps and rubella combined vaccine, live</keyword>
  <keyword>infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mumps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

